The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; Bayer; BeiGene; Clovis Oncology; Janssen-Cilag; Johnson & Johnson; Novartis; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; BeiGene; Clovis Oncology; Janssen-Cilag; Johnson & Johnson; Novartis; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; BeiGene; Clovis Oncology; Janssen-Cilag; Johnson & Johnson; Novartis; Pfizer; Sanofi
Research Funding - Clovis Oncology; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; BeiGene; Clovis Oncology; Janssen-Cilag; Johnson & Johnson; Novartis; Sanofi
Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies.
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics; Teon Therapeutics
Honoraria - Janssen; Johnson and Johnson
Consulting or Advisory Role - Beigene; Fortis; Fortis; Janssen Oncology; Teon Therapeutics; Tolero Pharmaceuticals; Ultragenyx Pharmaceuticals
Research Funding - Janssen (Inst)
Travel, Accommodations, Expenses - Janssen
 
Kim N. Chi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - AstraZeneca; Novartis
 
Simon Chowdhury
No Relationships to Disclose
 
Katherine B. Bevans
Employment - Janssen
 
Amitabha Bhaumik
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Byung Chung
Honoraria - Astellas Pharma; Ipsen; JW Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Janssen; Myovant Sciences; Pfizer; Roche
 
Lawrence Ivan Karsh
Stock and Other Ownership Interests - Swan Valley Medical
Honoraria - Astellas Pharma; Bayer; Janssen; Pfizer
Consulting or Advisory Role - 3D Biopsy; Astellas Pharma; AstraZeneca; Bayer; Dendreon; Ferring; Janssen
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Pfizer; Vaxiion
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioXcel Therapeutics (Inst); Bristol-Myers Squibb (Inst); CU Optics (Inst); CUSP (Inst); Dendreon (Inst); Epizyme (Inst); Exact Sciences (Inst); Ferring (Inst); FKD Therapies (Inst); Genentech/Roche (Inst); GenomeDx (Inst); Genomic Health (Inst); Janssen (Inst); Merck (Inst); Myovant Sciences (Inst); Nucleix (Inst); OncoCellMDx (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; Pfizer
 
Stephane Oudard
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi
Research Funding - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche
 
Peter De Porre
Employment - Johnson&Johnson
Stock and Other Ownership Interests - Johnson&Johnson
 
Sabine D. Brookman-May
Employment - Janssen Research & Development
Leadership - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Sharon Anne McCarthy
Employment - Janssen Oncology
Stock and Other Ownership Interests - Johnson and Johnson
 
Suneel Mundle
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Hirotsugu Uemura
Honoraria - Bayer; Bristol-Myers Squibb Japan; Janssen; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Sanofi
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Janssen; MSD; Pfizer
Research Funding - Astellas Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Takeda (Inst)
 
Matthew Raymond Smith
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen Oncology; Lilly; Novartis; Pfizer
Research Funding - Bayer (Inst); ESSA (Inst); Janssen Oncology (Inst); Lilly (Inst); ORIC Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Janssen; Lilly
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech; Janssen; Lilly; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pharmacyclics; Seagen
Research Funding - AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Clovis Oncology (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Nektar (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); TRACON Pharma (Inst)